Sunday, May 5, 2024
Home Client Page 2

Client

    Featured posts

    GeoVax (GOVX) Conference Call at 4:30 ET, the 29th.

    Client Editor / Curator -
    GeoVax to Host Conference Call at 4:30 PM ET GeoVax to Report 2023 Financial Results and Provide Corporate...

    GeoVax Reports Positive Interim Data From Phase 2 Clinical Trial!

    Client Editor / Curator -
    Results Demonstrate Potential Protective Immunity Against Multiple SARS-CoV-2 Variants We were having cocktails at...

    GeoVax Labs (GOVX) JP Morgan 2024 Healthcare Conference Transcript.

    Client Editor / Curator -
    (Presentation text bolding for emphasis by Editors of the Biotech Stock Review, not the company.

    Adding GeoVax (GOVX) $3.32 to Reverse Stock Split Watch List.

    Client Editor / Curator -
    Okay, Here's Our First Name for the Reverse Stock Split, Watch List. We'll Venture to Have 10 Names Added to Watch List...

    Research Report: Society Pass (SOPA) $0.22. Price Target $4.00.

    Client Editor / Curator -
    Three New Reports on Society Pass (SOPA) With Price Targets from $3.00 to $4.00. (All Report Archive)

    GeoVax (GOVX) Research Reports Archive

    Client Editor / Curator -
    Research Report Archive Reports from Robert LeBoyer at Noble Capital. Jeffrey Kraws and Karen Goldfarb at Crystal Research....

    Is David Dodd on to his Next Billion Dollar Payday for Shareholders?

    Client Editor / Curator -
    Huge News: Gedeptin® Therapy Demonstrated Safety, Stabilization and Shrinkage of Treated Tumors. GeoVax (GOVX) Completes Patient...

    Citius Pharmaceuticals, Inc. (CTXR) Reports Fiscal Full Year 2023 Financial Results and Provides Business...

    Client Editor / Curator -
    Mino-Lok® Pivotal Phase 3 trial enrollment completed; topline data expected 2Q 2024 LYMPHIR™ BLA resubmission on track for early 2024

    Adding Geovax (GOVX) to 2024 Biotech Watch List.

    Client Editor / Curator -
    GEOVAX (GOVX) $0.32 We added this to the Watch List earlier in the...

    LQR House (LQR) Commits to Postpone Public Offerings for the Foreseeable Future.

    Beverage News Editor / Curator -
    LQR House Initiates Warrants Cancellation and Commits to Postpone Public Offerings for the Foreseeable Future
    123...31Page 2 of 31

    Latest article

    We’re in Tampa for the Kentucky Derby.

    Client Editor / Curator -
    GeoVax (GOVX), Sees a Little Volume. Normally, we get a little nervous when one of the companies we...

    Institutional Analyst Newsletter. Citius (CTXR), GeoVax (GOVX.

    Institutional Analyst Newsletter Editor / Curator -
    DERBY WEEKEND - WE'RE HEADED TO TAMPA!HAT'S ON, DRINK'S UPADDING CITIUS PHARMA (CTXR) $0.66, TO WATCHLISTUPDATING GEOVAX LABS (GOVX) $1.43OUR $26...

    Adding Citius Pharma (CTXR) $0.66 to 2024 Watch List.

    Client Editor / Curator -
    Three Years Since we Last Added Citius (CTXR) to the Watch List, and it Looks Better Than Ever!
    The Internet Stock Review is one of Wall Streets oldest newsletters covering internet technology having launched in 1999. The Biotech Stock Review is rather old too, having launched in 2002. We make our money by purchasing stock with our services, so the better our client stocks do, the better we all do. And when we're wrong, we feel the pain too! See our research reports for important disclaimer details. Content is provided by Institutional Analyst Inc., the website is managed by Revelers.IO Media Group Inc. To see if your Company qualifies for coverage, call 310-594-8062
    Contact us: [email protected]
    © Managed by Revelers.IO Media Group Inc.